Publications by authors named "Bernd Schmitz-Draeger"

Article Synopsis
  • - The study analyzed the presence of tumor infiltrating lymphocytes (TILs) in muscle-invasive bladder cancer (MIBC) and found that certain patterns of TILs can indicate better outcomes for patients undergoing radical cystectomy.
  • - Researchers evaluated TILs in 241 MIBC patients using standard stained slides and additionally performed immunohistochemistry to count various immune cell types, correlating these findings with patient survival rates and tumor characteristics.
  • - Results revealed that a higher percentage (≥10%) of stromal TILs significantly correlated with better 5-year overall survival, disease-specific survival, and recurrence-free survival, marking it as a strong independent predictor for improved patient outcomes.
View Article and Find Full Text PDF

Background: Immune therapy has gained significant importance in managing urothelial cancer. The value of PD-L1 remains a matter of controversy, thus requiring an in-depth analysis of its biological and clinical relevance.

Methods: A total of 193 tumors of muscle-invasive bladder cancer patients (MIBC) were assessed with four PD-L1 assays.

View Article and Find Full Text PDF

Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine and, at least in the US, none of the tested agents had been approved for second-line treatment. This has changed with the advent of immune checkpoint blockade, including especially PD-1/PD-L1 inhibitors.

View Article and Find Full Text PDF